Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation

Background: The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transpl...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of cancer Vol. 116; no. 1; pp. 21 - 27
Main Authors Treister, Nathaniel, Nieder, Michael, Baggott, Christina, Olson, Ellen, Chen, Lu, Dang, Ha, Krailo, Mark, August, Amanda, Sung, Lillian
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 03.01.2017
Nature Publishing Group
Subjects
631/92/436/108
692/699/3020/3025
692/699/67/2332
692/700/565/545/576/1955
Adolescent
Adult
Biomedical and Life Sciences
Biomedicine
Calcium Phosphates - therapeutic use
Cancer
Cancer Research
Child
Child, Preschool
Clinical Study
Clinical trials
Drug dosages
Drug Resistance
Epidemiology
FDA approval
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Hospitals
Humans
Hypertonic Solutions - therapeutic use
Male
Medicine
Molecular Medicine
Morphine
Mucositis
Myeloablative Agonists - therapeutic use
Oncology
Pediatrics
Prevention
Stomatitis - etiology
Stomatitis - prevention & control
Teenagers
Transplantation Conditioning - adverse effects
Transplantation Conditioning - methods
Transplantation, Homologous
Transplants & implants
Treatment Outcome
Young Adult
Atlanta Georgia
United States > US
oral mucositis
hematopoietic cell transplantation
pediatrics
Online AccessGet full text
ISSN0007-0920
1532-1827
1532-1827
DOI10.1038/bjc.2016.380

Cover

Abstract Background: The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT). Methods: This was a Children’s Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0–10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO ⩾3). Results: The study enrolled 220 participants with a median age of 13.7 years (range 4.0–21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P =0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively ( P =0.44). There were no significant differences in any of the secondary end points between the groups. Conclusions: Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.
AbstractList The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT). This was a Children's Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0-10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO ⩾3). The study enrolled 220 participants with a median age of 13.7 years (range 4.0-21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P=0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively (P=0.44). There were no significant differences in any of the secondary end points between the groups. Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.
The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT).BACKGROUNDThe primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT).This was a Children's Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0-10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO ⩾3).METHODSThis was a Children's Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0-10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO ⩾3).The study enrolled 220 participants with a median age of 13.7 years (range 4.0-21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P=0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively (P=0.44). There were no significant differences in any of the secondary end points between the groups.RESULTSThe study enrolled 220 participants with a median age of 13.7 years (range 4.0-21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P=0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively (P=0.44). There were no significant differences in any of the secondary end points between the groups.Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.CONCLUSIONSCaphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.
Background: The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT). Methods: This was a Children's Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0-10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO [egs]3). Results: The study enrolled 220 participants with a median age of 13.7 years (range 4.0-21.9); 163 (74%) received allogeneic HCT. The mean ( plus or minus s.d.) duration of severe OM was not reduced among Caphosol (4.5 plus or minus 5.0 days) vs placebo (4.5 plus or minus 4.8; P=0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively (P=0.44). There were no significant differences in any of the secondary end points between the groups. Conclusions: Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.
Background: The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT). Methods: This was a Children’s Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0–10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO ⩾3). Results: The study enrolled 220 participants with a median age of 13.7 years (range 4.0–21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P =0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively ( P =0.44). There were no significant differences in any of the secondary end points between the groups. Conclusions: Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.
Background:The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT).Methods:This was a Children's Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0-10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO [= or >, slanted]3).Results:The study enrolled 220 participants with a median age of 13.7 years (range 4.0-21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P=0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively (P=0.44). There were no significant differences in any of the secondary end points between the groups.Conclusions:Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.
Author Olson, Ellen
Dang, Ha
Krailo, Mark
August, Amanda
Chen, Lu
Treister, Nathaniel
Sung, Lillian
Nieder, Michael
Baggott, Christina
Author_xml – sequence: 1
  givenname: Nathaniel
  surname: Treister
  fullname: Treister, Nathaniel
  email: ntreister@partners.org
  organization: Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine
– sequence: 2
  givenname: Michael
  surname: Nieder
  fullname: Nieder, Michael
  organization: Blood and Marrow Transplant Department, Moffitt Cancer Center, Tampa, FL and Johns Hopkins All Children’s Hospital
– sequence: 3
  givenname: Christina
  surname: Baggott
  fullname: Baggott, Christina
  organization: Pediatric Hematology-Oncology, Stanford Medical Center
– sequence: 4
  givenname: Ellen
  surname: Olson
  fullname: Olson, Ellen
  organization: Aflac Cancer and Blood Disorders Service, Children’s Healthcare of Atlanta
– sequence: 5
  givenname: Lu
  surname: Chen
  fullname: Chen, Lu
  organization: Children’s Oncology Group
– sequence: 6
  givenname: Ha
  surname: Dang
  fullname: Dang, Ha
  organization: Children’s Oncology Group, Department of Preventive Medicine, University of Southern California
– sequence: 7
  givenname: Mark
  surname: Krailo
  fullname: Krailo, Mark
  organization: Children’s Oncology Group, Department of Preventive Medicine, University of Southern California
– sequence: 8
  givenname: Amanda
  surname: August
  fullname: August, Amanda
  organization: Children’s Mercy Hospital
– sequence: 9
  givenname: Lillian
  surname: Sung
  fullname: Sung, Lillian
  organization: Division of Haematology/Oncology, The Hospital for Sick Children
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27875526$$D View this record in MEDLINE/PubMed
BookMark eNqNks1r3DAQxUVJaDbb3nougl56qLeybNnypVCWfkEgl_QsJO04q8WWXEleyH_fMZuENLTQkxDzm8e8N3NJznzwQMibkm1KVsmP5mA3nJXNppLsBVmVouJFKXl7RlaMsbZgHWcX5DKlA347JtuX5IK3shWCNyuy3-ppH1IYaB8inSIcwWcXPA09DVEPdJxtSC67RJ2nE-ycztFZOt7BELQZdHZHoHsNo85hCg4yFi0MA81R-zQN2me9CL4i570eEry-f9fk59cvN9vvxdX1tx_bz1eFrTrJCisra2zPTNfv-qbVpi25FV0vwUhRSrHTQpoGJGOWS9lKaUuLnhpRgdVg-mpNPp10p9mMsLNoB22oKbpRxzsVtFN_Vrzbq9twVIJjinWLAu_vBWL4NUPKanRpcaQ9hDkpHKKrZceb-j_QusL0Be5kTd49Qw9hjh6TWAQFEzWKIvX26fCPUz_sCwF-AmwMKUXolXWnfNGLG1TJ1HIUCo9CLUeh8Ciw6cOzpgfdf-DFCU-I-VuIT0b9G_8bl-DJ-Q
CODEN BJCAAI
CitedBy_id crossref_primary_10_1002_pbc_26856
crossref_primary_10_1177_1078155219850298
crossref_primary_10_1182_bloodadvances_2020002039
crossref_primary_10_1016_j_ejpb_2018_04_025
crossref_primary_10_1002_pbc_30568
crossref_primary_10_3389_fphar_2017_00354
crossref_primary_10_1016_j_bulcan_2021_01_018
crossref_primary_10_1007_s40487_018_0060_z
crossref_primary_10_3390_ijerph17072464
crossref_primary_10_1111_odi_13918
crossref_primary_10_5604_01_3001_0014_5716
crossref_primary_10_1007_s00520_020_05803_4
crossref_primary_10_1007_s00520_019_04887_x
crossref_primary_10_1186_s12903_021_01914_4
crossref_primary_10_1111_scd_12358
crossref_primary_10_1002_pbc_28520
crossref_primary_10_1007_s00520_023_07858_5
crossref_primary_10_1111_odi_14167
crossref_primary_10_1038_s41409_020_0818_4
crossref_primary_10_1002_pbc_27403
crossref_primary_10_1007_s00520_023_08030_9
crossref_primary_10_1007_s11864_021_00823_6
crossref_primary_10_1097_SPC_0000000000000264
Cites_doi 10.1111/j.1651-2227.1999.tb00011.x
10.1007/s00520-009-0618-2
10.1038/nrc1318
10.1016/j.bbmt.2012.04.013
10.1016/j.ejca.2010.09.018
10.1007/s00520-007-0323-y
10.1016/j.transproceed.2011.08.053
10.1056/NEJMoa040125
10.1111/ecc.12073
10.1016/j.bbmt.2009.07.004
10.1002/(SICI)1097-4644(1998)72:30/31+<147::AID-JCB19>3.0.CO;2-F
10.1016/j.ejon.2014.07.011
10.1001/jama.285.15.2006
10.1002/cncr.11671
10.1111/petr.12192
10.1016/j.bbmt.2007.03.004
10.1007/s00520-013-2015-0
10.1007/s00520-011-1211-z
10.1200/JCO.2001.19.8.2201
10.1016/j.jpain.2014.01.494
10.1016/j.bbmt.2014.02.025
10.1038/sj.bmt.1703870
10.1016/j.ejon.2008.05.010
10.1038/bmt.2010.184
10.1111/j.1601-0825.2006.01258.x
10.1016/0002-9343(94)90009-4
10.6004/jnccn.2010.0076
10.1007/s005209900095
10.1136/bmjspcare-2014-000804
ContentType Journal Article
Copyright The Author(s) 2016
Copyright Nature Publishing Group Jan 3, 2017
Copyright © 2016 Cancer Research UK 2016 Cancer Research UK
Copyright_xml – notice: The Author(s) 2016
– notice: Copyright Nature Publishing Group Jan 3, 2017
– notice: Copyright © 2016 Cancer Research UK 2016 Cancer Research UK
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TO
7U9
7X7
7XB
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/bjc.2016.380
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (ProQuest)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database ProQuest
Biological Science Database
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Oncogenes and Growth Factors Abstracts

ProQuest Central Student
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Caphosol for mucositis prevention in children
EISSN 1532-1827
EndPage 27
ExternalDocumentID PMC5220147
4292464291
27875526
10_1038_bjc_2016_380
Genre Multicenter Study
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Atlanta Georgia
United States--US
GeographicLocations_xml – name: Atlanta Georgia
– name: United States--US
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: U10 CA180899
– fundername: NCI NIH HHS
  grantid: U10 CA098413
– fundername: NCI NIH HHS
  grantid: U10 CA180886
– fundername: NCI NIH HHS
  grantid: U10 CA098543
– fundername: NCI NIH HHS
  grantid: UG1 CA189955
GroupedDBID ---
-Q-
0R~
23N
36B
39C
3V.
4.4
406
53G
5GY
5RE
6J9
70F
7RV
7X7
88E
8AO
8C1
8FI
8FJ
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAWTL
AAYZH
AAZLF
ABAKF
ABLJU
ABOCM
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACPRK
ACRQY
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALMA_UNASSIGNED_HOLDINGS
AMYLF
AN0
AOIJS
ASPBG
AVWKF
AXYYD
AZFZN
BAWUL
BBNVY
BENPR
BHPHI
BKEYQ
BKKNO
BNQBC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
E3Z
EAP
EBLON
EBS
EE.
EIOEI
EJD
EMB
ESX
EX3
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FRJ
FSGXE
FYUFA
GX1
HCIFZ
HMCUK
HVGLF
HYE
HZ~
IH2
IWAJR
JSO
JZLTJ
KQ8
M1P
M7P
NAO
NAPCQ
NQJWS
O9-
OK1
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
ROL
RPM
SNX
SNYQT
SOHCF
SOJ
SRMVM
SWTZT
TAOOD
TBHMF
TDRGL
TR2
UKHRP
W2D
WH7
WOW
~02
AAFWJ
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7U9
7XB
8FE
8FH
8FK
ABRTQ
AZQEC
DWQXO
GNUQQ
H94
K9.
LK8
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c3980-c83cbcf0b9fdf67ab712c59f8eb85185da58b6e800c288788c1c087653ecaebf3
IEDL.DBID 7X7
ISSN 0007-0920
1532-1827
IngestDate Thu Aug 21 18:10:34 EDT 2025
Fri Jul 11 07:41:06 EDT 2025
Fri Jul 11 08:38:56 EDT 2025
Fri Jul 25 08:59:07 EDT 2025
Wed Feb 19 02:43:13 EST 2025
Tue Jul 01 01:29:44 EDT 2025
Thu Apr 24 23:12:52 EDT 2025
Fri Feb 21 02:39:47 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords oral mucositis
hematopoietic cell transplantation
pediatrics
Language English
License From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3980-c83cbcf0b9fdf67ab712c59f8eb85185da58b6e800c288788c1c087653ecaebf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.nature.com/articles/bjc.2016.380
PMID 27875526
PQID 1855054948
PQPubID 41855
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5220147
proquest_miscellaneous_1859489264
proquest_miscellaneous_1843920515
proquest_journals_1855054948
pubmed_primary_27875526
crossref_citationtrail_10_1038_bjc_2016_380
crossref_primary_10_1038_bjc_2016_380
springer_journals_10_1038_bjc_2016_380
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20170103
PublicationDateYYYYMMDD 2017-01-03
PublicationDate_xml – month: 1
  year: 2017
  text: 20170103
  day: 3
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle British journal of cancer
PublicationTitleAbbrev Br J Cancer
PublicationTitleAlternate Br J Cancer
PublicationYear 2017
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Cheng (CR5) 2009; 17
Papas, Clark, Martuscelli, O'Loughlin, Johansen, Miller (CR13) 2003; 31
Kamdar (CR9) 2008
Svanberg, Ohrn, Birgegard (CR24) 2015; 19
Tomlinson, Judd, Hendershot, Maloney, Sung (CR27) 2007; 15
Elting, Shih, Stiff, Bensinger, Cantor, Cooksley, Spielberger, Emmanoulides (CR8) 2007; 13
Sonis (CR18) 2004; 4
Wasko-Grabowska, Rzepecki, Oborska, Barzal, Gawronski, Mlot, Szczylik (CR30) 2011; 43
Vagliano, Feraut, Gobetto, Trunfio, Errico, Campani, Costazza, Mega, Matozzo, Berni, Alberani, Banfi, Martinelli, Munaron, Orlando, Lubiato, Leanza, Guerrato, Rossetti, Messina, Barzetti, Satta, Dimonte (CR28) 2011; 46
Bochud, Calandra, Francioli (CR4) 1994; 97
CR31
Tomlinson, Ethier, Judd, Doyle, Gassas, Naqvi, Sung (CR25) 2011; 47
Elting, Cooksley, Chambers, Cantor, Manzullo, Rubenstein (CR7) 2003; 98
Raphael, den Boer, Kollen, Mekelenkamp, Abbink, Kaspers, Zomer-Kooijker, Molmans, Tissing (CR15) 2014; 22
Scully, Sonis, Diz (CR17) 2006; 12
Quinn (CR14) 2013; 22
Vitale, Violago, Cofnas, Bishop, Jin, Bhatia, Kung, George, Garvin, Satwani (CR29) 2014; 18
Bellm, Epstein, Rose-Ped, Martin, Fuchs (CR3) 2000; 8
Srinivasan, Kasow, Cross, Parrish, Wang, Srivastava, Cai, Panetta, Leung (CR21) 2012; 18
An, Goetzl, Lee (CR1) 1998; 30–31
Rennie (CR16) 2001; 285
Tomlinson, Gibson, Treister, Baggott, Judd, Hendershot, Maloney, Doyle, Feldman, Sung (CR26) 2008; 12
Ljungman, Gordh, Sorensen, Kreuger (CR10) 1999; 88
Nooka, Johnson, Kaufman, Flowers, Langston, Steuer, Graiser, Ali, Shah, Rangaraju, Nickleach, Gao, Lonial, Waller (CR12) 2014; 20
Sonis, Oster, Fuchs, Bellm, Bradford, Edelsberg, Hayden, Eilers, Epstein, LeVeque, Miller, Peterson, Schubert, Spijkervet, Horowitz (CR19) 2001; 19
CR23
Spielberger, Stiff, Bensinger, Gentile, Weisdorf, Kewalramani, Shea, Yanovich, Hansen, Noga, McCarty, LeMaistre, Sung, Blazar, Elhardt, Chen, Emmanouilides (CR20) 2004; 351
Swarm (CR22) 2010; 8
Chou, Cruciani, Fiellin, Compton, Farrar, Haigney, Inturrisi, Knight, Otis-Green, Marcus, Mehta, Meyer, Portenoy, Savage, Strain, Walsh, Zeltzer (CR6) 2014; 15
Manji, Tomlinson, Ethier, Gassas, Maloney, Sung (CR11) 2012; 20
Bacigalupo, Ballen, Rizzo, Giralt, Lazarus, Ho, Apperley, Slavin, Pasquini, Sandmaier, Barrett, Blaise, Lowski, Horowitz (CR2) 2009; 15
A Wasko-Grabowska (BFbjc2016380_CR30) 2011; 43
BFbjc2016380_CR23
LS Elting (BFbjc2016380_CR8) 2007; 13
ST Sonis (BFbjc2016380_CR18) 2004; 4
A Srinivasan (BFbjc2016380_CR21) 2012; 18
AK Nooka (BFbjc2016380_CR12) 2014; 20
R Spielberger (BFbjc2016380_CR20) 2004; 351
D Tomlinson (BFbjc2016380_CR27) 2007; 15
ST Sonis (BFbjc2016380_CR19) 2001; 19
D Tomlinson (BFbjc2016380_CR25) 2011; 47
R Chou (BFbjc2016380_CR6) 2014; 15
A Bacigalupo (BFbjc2016380_CR2) 2009; 15
MF Raphael (BFbjc2016380_CR15) 2014; 22
R Swarm (BFbjc2016380_CR22) 2010; 8
M Kamdar (BFbjc2016380_CR9) 2008
BFbjc2016380_CR31
PY Bochud (BFbjc2016380_CR4) 1994; 97
A Manji (BFbjc2016380_CR11) 2012; 20
C Scully (BFbjc2016380_CR17) 2006; 12
B Quinn (BFbjc2016380_CR14) 2013; 22
L Vagliano (BFbjc2016380_CR28) 2011; 46
KK Cheng (BFbjc2016380_CR5) 2009; 17
KM Vitale (BFbjc2016380_CR29) 2014; 18
AS Papas (BFbjc2016380_CR13) 2003; 31
G Ljungman (BFbjc2016380_CR10) 1999; 88
LS Elting (BFbjc2016380_CR7) 2003; 98
LA Bellm (BFbjc2016380_CR3) 2000; 8
A Svanberg (BFbjc2016380_CR24) 2015; 19
D Rennie (BFbjc2016380_CR16) 2001; 285
D Tomlinson (BFbjc2016380_CR26) 2008; 12
S An (BFbjc2016380_CR1) 1998; 30–31
25224595 - Eur J Oncol Nurs. 2015 Feb;19(1):50-3
17724620 - Support Care Cancer. 2007 Nov;15(11):1251-8
12692611 - Bone Marrow Transplant. 2003 Apr;31(8):705-12
8092175 - Am J Med. 1994 Sep;97(3):256-64
24823628 - Pediatr Transplant. 2014 Mar;18(2):211-6
24197056 - Support Care Cancer. 2014 Jan;22(1):3-6
19896087 - Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
20818449 - Bone Marrow Transplant. 2011 May;46(5):727-32
11304772 - J Clin Oncol. 2001 Apr 15;19(8):2201-5
24607557 - Biol Blood Marrow Transplant. 2014 Jun;20(6):852-7
19322593 - Support Care Cancer. 2009 Jul;17(7):829-37
21681385 - Support Care Cancer. 2012 Jun;20(6):1251-8
11308440 - JAMA. 2001 Apr 18;285(15):2006-7
25818385 - BMJ Support Palliat Care. 2017 Mar;7(1):7-16
15602019 - N Engl J Med. 2004 Dec 16;351(25):2590-8
14508842 - Cancer. 2003 Oct 1;98(7):1531-9
21996239 - Transplant Proc. 2011 Oct;43(8):3111-3
10419246 - Acta Paediatr. 1999 Jun;88(6):623-30
17580258 - Biol Blood Marrow Transplant. 2007 Jul;13(7):806-13
23731197 - Eur J Cancer Care (Engl). 2013 Sep;22(5):564-79
9893266 - J Cell Biochem Suppl. 1998;30-31:147-57
22542710 - Biol Blood Marrow Transplant. 2012 Aug;18(8):1309-14
10650895 - Support Care Cancer. 2000 Jan;8(1):33-9
18842459 - Eur J Oncol Nurs. 2008 Dec;12 (5):469-75
24685458 - J Pain. 2014 Apr;15(4):321-37
15057287 - Nat Rev Cancer. 2004 Apr;4(4):277-84
20947338 - Eur J Cancer. 2011 Feb;47(3):383-8
16700732 - Oral Dis. 2006 May;12(3):229-41
References_xml – volume: 88
  start-page: 623
  issue: 6
  year: 1999
  end-page: 630
  ident: CR10
  article-title: Pain in paediatric oncology: interviews with children, adolescents and their parents
  publication-title: Acta Paediatr
  doi: 10.1111/j.1651-2227.1999.tb00011.x
– volume: 17
  start-page: 829
  issue: 7
  year: 2009
  end-page: 837
  ident: CR5
  article-title: Oral mucositis: a phenomenological study of pediatric patients' and their parents' perspectives and experiences
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-009-0618-2
– volume: 4
  start-page: 277
  issue: 4
  year: 2004
  end-page: 284
  ident: CR18
  article-title: The pathobiology of mucositis
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1318
– volume: 18
  start-page: 1309
  issue: 8
  year: 2012
  end-page: 1314
  ident: CR21
  article-title: Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.04.013
– volume: 47
  start-page: 383
  issue: 3
  year: 2011
  end-page: 388
  ident: CR25
  article-title: Reliability and construct validity of the oral mucositis daily questionnaire in children with cancer
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2010.09.018
– volume: 15
  start-page: 1251
  issue: 11
  year: 2007
  end-page: 1258
  ident: CR27
  article-title: Measurement of oral mucositis in children: a review of the literature
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-007-0323-y
– volume: 43
  start-page: 3111
  issue: 8
  year: 2011
  end-page: 3113
  ident: CR30
  article-title: Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2011.08.053
– volume: 351
  start-page: 2590
  issue: 25
  year: 2004
  end-page: 2598
  ident: CR20
  article-title: Palifermin for oral mucositis after intensive therapy for hematologic cancers
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa040125
– volume: 22
  start-page: 564
  issue: 5
  year: 2013
  end-page: 579
  ident: CR14
  article-title: Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data
  publication-title: Eur J Cancer Care (Engl)
  doi: 10.1111/ecc.12073
– volume: 15
  start-page: 1628
  issue: 12
  year: 2009
  end-page: 1633
  ident: CR2
  article-title: Defining the intensity of conditioning regimens: working definitions
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2009.07.004
– volume: 30–31
  start-page: 147
  year: 1998
  end-page: 157
  ident: CR1
  article-title: Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate
  publication-title: J Cell Biochem Suppl
  doi: 10.1002/(SICI)1097-4644(1998)72:30/31+<147::AID-JCB19>3.0.CO;2-F
– volume: 19
  start-page: 50
  issue: 1
  year: 2015
  end-page: 53
  ident: CR24
  article-title: Caphosol((R)) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study
  publication-title: Eur J Oncol Nurs
  doi: 10.1016/j.ejon.2014.07.011
– ident: CR23
– volume: 285
  start-page: 2006
  issue: 15
  year: 2001
  end-page: 2007
  ident: CR16
  article-title: CONSORT revised—improving the reporting of randomized trials
  publication-title: JAMA
  doi: 10.1001/jama.285.15.2006
– year: 2008
  ident: CR9
  publication-title: Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain
– volume: 98
  start-page: 1531
  issue: 7
  year: 2003
  end-page: 1539
  ident: CR7
  article-title: The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis
  publication-title: Cancer
  doi: 10.1002/cncr.11671
– volume: 18
  start-page: 211
  issue: 2
  year: 2014
  end-page: 216
  ident: CR29
  article-title: Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases
  publication-title: Pediatr Transplant
  doi: 10.1111/petr.12192
– volume: 13
  start-page: 806
  issue: 7
  year: 2007
  end-page: 813
  ident: CR8
  article-title: Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2007.03.004
– volume: 22
  start-page: 3
  issue: 1
  year: 2014
  end-page: 6
  ident: CR15
  article-title: Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?: Results from a prospective multicenter double blind randomized controlled trial
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-013-2015-0
– volume: 20
  start-page: 1251
  issue: 6
  year: 2012
  end-page: 1258
  ident: CR11
  article-title: Psychometric properties of the Oral Mucositis Daily Questionnaire for child self-report and importance of mucositis in children treated with chemotherapy
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-011-1211-z
– volume: 19
  start-page: 2201
  issue: 8
  year: 2001
  end-page: 2205
  ident: CR19
  article-title: Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2001.19.8.2201
– ident: CR31
– volume: 15
  start-page: 321
  issue: 4
  year: 2014
  end-page: 337
  ident: CR6
  article-title: Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society
  publication-title: J Pain
  doi: 10.1016/j.jpain.2014.01.494
– volume: 20
  start-page: 852
  issue: 6
  year: 2014
  end-page: 857
  ident: CR12
  article-title: Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2014.02.025
– volume: 31
  start-page: 705
  issue: 8
  year: 2003
  end-page: 712
  ident: CR13
  article-title: A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1703870
– volume: 12
  start-page: 469
  issue: 5
  year: 2008
  end-page: 475
  ident: CR26
  article-title: Challenges of mucositis assessment in children: expert opinion
  publication-title: Eur J Oncol Nurs
  doi: 10.1016/j.ejon.2008.05.010
– volume: 46
  start-page: 727
  issue: 5
  year: 2011
  end-page: 732
  ident: CR28
  article-title: Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicentre study
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2010.184
– volume: 12
  start-page: 229
  issue: 3
  year: 2006
  end-page: 241
  ident: CR17
  article-title: Oral mucositis
  publication-title: Oral Dis
  doi: 10.1111/j.1601-0825.2006.01258.x
– volume: 8
  start-page: 33
  issue: 1
  year: 2000
  end-page: 39
  ident: CR3
  article-title: Patient reports of complications of bone marrow transplantation
  publication-title: Support Care Cancer
– volume: 97
  start-page: 256
  issue: 3
  year: 1994
  end-page: 264
  ident: CR4
  article-title: Bacteremia due to viridans streptococci in neutropenic patients: a review
  publication-title: Am J Med
  doi: 10.1016/0002-9343(94)90009-4
– volume: 8
  start-page: 1046
  issue: 9
  year: 2010
  end-page: 1086
  ident: CR22
  article-title: Clinical practice guidelines in oncology: adult cancer pain
  publication-title: J Natl Comprehensive Cancer Netw
  doi: 10.6004/jnccn.2010.0076
– volume: 88
  start-page: 623
  issue: 6
  year: 1999
  ident: BFbjc2016380_CR10
  publication-title: Acta Paediatr
  doi: 10.1111/j.1651-2227.1999.tb00011.x
– volume: 17
  start-page: 829
  issue: 7
  year: 2009
  ident: BFbjc2016380_CR5
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-009-0618-2
– volume: 351
  start-page: 2590
  issue: 25
  year: 2004
  ident: BFbjc2016380_CR20
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa040125
– volume: 8
  start-page: 33
  issue: 1
  year: 2000
  ident: BFbjc2016380_CR3
  publication-title: Support Care Cancer
  doi: 10.1007/s005209900095
– volume: 15
  start-page: 321
  issue: 4
  year: 2014
  ident: BFbjc2016380_CR6
  publication-title: J Pain
  doi: 10.1016/j.jpain.2014.01.494
– volume: 20
  start-page: 1251
  issue: 6
  year: 2012
  ident: BFbjc2016380_CR11
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-011-1211-z
– volume: 19
  start-page: 2201
  issue: 8
  year: 2001
  ident: BFbjc2016380_CR19
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2001.19.8.2201
– volume: 285
  start-page: 2006
  issue: 15
  year: 2001
  ident: BFbjc2016380_CR16
  publication-title: JAMA
  doi: 10.1001/jama.285.15.2006
– volume: 97
  start-page: 256
  issue: 3
  year: 1994
  ident: BFbjc2016380_CR4
  publication-title: Am J Med
  doi: 10.1016/0002-9343(94)90009-4
– volume: 13
  start-page: 806
  issue: 7
  year: 2007
  ident: BFbjc2016380_CR8
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2007.03.004
– ident: BFbjc2016380_CR23
  doi: 10.1136/bmjspcare-2014-000804
– volume: 18
  start-page: 211
  issue: 2
  year: 2014
  ident: BFbjc2016380_CR29
  publication-title: Pediatr Transplant
  doi: 10.1111/petr.12192
– volume: 22
  start-page: 3
  issue: 1
  year: 2014
  ident: BFbjc2016380_CR15
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-013-2015-0
– volume: 47
  start-page: 383
  issue: 3
  year: 2011
  ident: BFbjc2016380_CR25
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2010.09.018
– volume-title: Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain
  year: 2008
  ident: BFbjc2016380_CR9
– volume: 20
  start-page: 852
  issue: 6
  year: 2014
  ident: BFbjc2016380_CR12
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2014.02.025
– volume: 30–31
  start-page: 147
  year: 1998
  ident: BFbjc2016380_CR1
  publication-title: J Cell Biochem Suppl
  doi: 10.1002/(SICI)1097-4644(1998)72:30/31+<147::AID-JCB19>3.0.CO;2-F
– volume: 31
  start-page: 705
  issue: 8
  year: 2003
  ident: BFbjc2016380_CR13
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1703870
– volume: 15
  start-page: 1628
  issue: 12
  year: 2009
  ident: BFbjc2016380_CR2
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2009.07.004
– volume: 98
  start-page: 1531
  issue: 7
  year: 2003
  ident: BFbjc2016380_CR7
  publication-title: Cancer
  doi: 10.1002/cncr.11671
– volume: 43
  start-page: 3111
  issue: 8
  year: 2011
  ident: BFbjc2016380_CR30
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2011.08.053
– volume: 19
  start-page: 50
  issue: 1
  year: 2015
  ident: BFbjc2016380_CR24
  publication-title: Eur J Oncol Nurs
  doi: 10.1016/j.ejon.2014.07.011
– volume: 22
  start-page: 564
  issue: 5
  year: 2013
  ident: BFbjc2016380_CR14
  publication-title: Eur J Cancer Care (Engl)
  doi: 10.1111/ecc.12073
– volume: 46
  start-page: 727
  issue: 5
  year: 2011
  ident: BFbjc2016380_CR28
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2010.184
– volume: 4
  start-page: 277
  issue: 4
  year: 2004
  ident: BFbjc2016380_CR18
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1318
– volume: 8
  start-page: 1046
  issue: 9
  year: 2010
  ident: BFbjc2016380_CR22
  publication-title: J Natl Comprehensive Cancer Netw
  doi: 10.6004/jnccn.2010.0076
– volume: 12
  start-page: 229
  issue: 3
  year: 2006
  ident: BFbjc2016380_CR17
  publication-title: Oral Dis
  doi: 10.1111/j.1601-0825.2006.01258.x
– volume: 18
  start-page: 1309
  issue: 8
  year: 2012
  ident: BFbjc2016380_CR21
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.04.013
– volume: 12
  start-page: 469
  issue: 5
  year: 2008
  ident: BFbjc2016380_CR26
  publication-title: Eur J Oncol Nurs
  doi: 10.1016/j.ejon.2008.05.010
– ident: BFbjc2016380_CR31
– volume: 15
  start-page: 1251
  issue: 11
  year: 2007
  ident: BFbjc2016380_CR27
  publication-title: Support Care Cancer
  doi: 10.1007/s00520-007-0323-y
– reference: 10650895 - Support Care Cancer. 2000 Jan;8(1):33-9
– reference: 12692611 - Bone Marrow Transplant. 2003 Apr;31(8):705-12
– reference: 14508842 - Cancer. 2003 Oct 1;98(7):1531-9
– reference: 17580258 - Biol Blood Marrow Transplant. 2007 Jul;13(7):806-13
– reference: 16700732 - Oral Dis. 2006 May;12(3):229-41
– reference: 24607557 - Biol Blood Marrow Transplant. 2014 Jun;20(6):852-7
– reference: 17724620 - Support Care Cancer. 2007 Nov;15(11):1251-8
– reference: 19896087 - Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
– reference: 21681385 - Support Care Cancer. 2012 Jun;20(6):1251-8
– reference: 11304772 - J Clin Oncol. 2001 Apr 15;19(8):2201-5
– reference: 24823628 - Pediatr Transplant. 2014 Mar;18(2):211-6
– reference: 11308440 - JAMA. 2001 Apr 18;285(15):2006-7
– reference: 25224595 - Eur J Oncol Nurs. 2015 Feb;19(1):50-3
– reference: 21996239 - Transplant Proc. 2011 Oct;43(8):3111-3
– reference: 10419246 - Acta Paediatr. 1999 Jun;88(6):623-30
– reference: 22542710 - Biol Blood Marrow Transplant. 2012 Aug;18(8):1309-14
– reference: 9893266 - J Cell Biochem Suppl. 1998;30-31:147-57
– reference: 20818449 - Bone Marrow Transplant. 2011 May;46(5):727-32
– reference: 20947338 - Eur J Cancer. 2011 Feb;47(3):383-8
– reference: 15602019 - N Engl J Med. 2004 Dec 16;351(25):2590-8
– reference: 24197056 - Support Care Cancer. 2014 Jan;22(1):3-6
– reference: 18842459 - Eur J Oncol Nurs. 2008 Dec;12 (5):469-75
– reference: 25818385 - BMJ Support Palliat Care. 2017 Mar;7(1):7-16
– reference: 15057287 - Nat Rev Cancer. 2004 Apr;4(4):277-84
– reference: 8092175 - Am J Med. 1994 Sep;97(3):256-64
– reference: 19322593 - Support Care Cancer. 2009 Jul;17(7):829-37
– reference: 24685458 - J Pain. 2014 Apr;15(4):321-37
– reference: 23731197 - Eur J Cancer Care (Engl). 2013 Sep;22(5):564-79
SSID ssj0009087
Score 2.3589826
Snippet Background: The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning,...
The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the...
Background:The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning,...
Background: The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning,...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 21
SubjectTerms 631/92/436/108
692/699/3020/3025
692/699/67/2332
692/700/565/545/576/1955
Adolescent
Adult
Biomedical and Life Sciences
Biomedicine
Calcium Phosphates - therapeutic use
Cancer
Cancer Research
Child
Child, Preschool
Clinical Study
Clinical trials
Drug dosages
Drug Resistance
Epidemiology
FDA approval
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Hospitals
Humans
Hypertonic Solutions - therapeutic use
Male
Medicine
Molecular Medicine
Morphine
Mucositis
Myeloablative Agonists - therapeutic use
Oncology
Pediatrics
Prevention
Stomatitis - etiology
Stomatitis - prevention & control
Teenagers
Transplantation Conditioning - adverse effects
Transplantation Conditioning - methods
Transplantation, Homologous
Transplants & implants
Treatment Outcome
Young Adult
SummonAdditionalLinks – databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ1NT9wwEIZHK5BQLxW00KZA5UrAhYYm9jpxjmgFWiHBCSRuke21tYuWJKLLgX_PjJMsLLRVb5E8kZyMP17bM48BDmyhkizxPDYGu9swk_g0SXmstU98YRPpPOUOX15l45vhxa28HcDPPhcmBO0HpGUYpvvosF_mjniDaXYiFC7Q1wnaTu15lI1eELuJagmZtPlW8KQLc0-EWnl7dQJ6pyrfB0e-OSENE8_5JnzsFCM7beu4BQNXfYKNy-5M_DNMR7qZ1tiEGOpP1nRIprpitWeUfs_uKSid0EVsVrGmv5qD3T-5ea3NPJC_2VQTvLVu6hllNTLaz2eLAD6f6zY7qdqGm_Oz69E47u5PiK1AF8RWCWusT0zhJz7LtclTbmXhlTOos5ScaKlM5lAyWo5jjVI2tUSok8JZ7YwXO7BW1ZX7CgzdJqR3Fhdn6dDlXkuHwlAq54daWCUjOO5_amk7uDjdcTEvwyG3UCW6oCQXlOiCCA6X1k0L1fiL3V7vn7LrWr_LlBBskqg2EfxYFmOnoD-jK1c_kg3qLE7X1_zLhkg1BQrCCL60Ll9WhuMwJiXPIshXGsPSgKDcqyXVbBrg3KhncdWZR3DUN5tXVf_DN377X8Nd-MBJUoQQuD1YWzw8un0URAvzPfSDZ11FDAo
  priority: 102
  providerName: Springer Nature
Title Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
URI https://link.springer.com/article/10.1038/bjc.2016.380
https://www.ncbi.nlm.nih.gov/pubmed/27875526
https://www.proquest.com/docview/1855054948
https://www.proquest.com/docview/1843920515
https://www.proquest.com/docview/1859489264
https://pubmed.ncbi.nlm.nih.gov/PMC5220147
Volume 116
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ1Nb9QwEIZH0EqIC6J8BtrKSMAFhSb2OnFOqI1aVUitEKLS3iLba2u32saBbg_8e2YSZ9tS6CVKlDkknrHzxh4_A_DeViorMs9TY7C7TQqJZ7Ocp1r7zFc2k87T3uGT0-L4bPJ1Kqdxwu0yplWOY2I_UM-CpTnyvZzIW5JgJl-6nylVjaLV1VhC4yFsErqMUrrKaXkN3c3UwMyk6biKZzHxPRNqz5wTvzAvPgsCQt78JN3RmXfTJf9aM-0_RUdP4UnUkGx_cPoWPHDtM3h0ElfJn8O81t08YFAxVKSsi5Cm0LLgGW3IZxeUpk4wI7ZoWTcW62AXv90yaLPsWeBsrgnnGrqwoH2OjGb42apHoS_1sF-pfQFnR4c_6uM0VlRIrUCnpFYJa6zPTOVnvii1KXNuZeWVM6i8lJxpqUzhUERajqOPUja3xKyTwlntjBcvYaMNrXsNDB0ppHcWf9fyiSu9lg6lolTOT7SwSibwaWzUxkbcOFW9WDb9srdQDbqgIRc06IIEPqytuwGz8R-77dE_Texsl811aCTwbn0buwm1jG5duCIbVF6cCtrcZ0PsmgolYgKvBpevH4bjwCYlLxIobwXD2oAw3bfvtIt5j-tGhYv_oWUCH8ewufHo_3jHN_e_41t4zEla9Klw27Cx-nXldlAYrcxuH_14VHW-C5sHh6ffvuNVXdR_AMhOE5I
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dTxQxEJ_gkagvxm8XUWsivpiV3Xa7130wRhFyCHcxBhLelrbX5o4cu6scMfxT_o3O7McBorzxtkknm7Yz0_7amf4G4I3NVJRGnofGoLslqcSvccxDrX3kMxtJ5-nt8HCUDvaTrwfyYAl-d29hKK2yWxPrhXpcWrojX4-JeUsSmcnH6kdIVaMoutqV0GjMYsed_cIj28mH7S-o3zXOtzb3NgZhW1UgtAI7FlolrLE-Mpkf-7SvTT_mVmZeOYPoQ8mxlsqkDoGU5eiBStnYEm-bFM5qZ7zA_96C5UTgUaYHy583R9--n9P8Rqph6aQLwIxHbap9JNS6OSLGxDh9L4iC8uImeAXZXk3Q_CtKW29-W_fhXota2afGzB7Akisewu1hG5d_BJMNXU1KNGOGGJhVLS1UWbDSM6IAYMeUGE_0SWxasKorD8KOz9ys1GZWs4-ziSYC2bIqp_SyklFMgc1r8vWZbl5IFY9h_0Zm-wn0irJwz4Ch6QjpncUDYpy4vtfSITiVyvlEC6tkAO-6Sc1tS3BOdTZmeR1oFypHFeSkghxVEMDaQrpqiD3-I7fa6Sdv3fskPzfGAF4vmtExaWZ04cpTkkGsx6mEznUyxJaTISgN4Gmj8kVnOC6lUvI0gP4lY1gIEDH45ZZiOqkJwhFT48m3H8DbzmwudP0fY1y5foyv4M5gb7ib726Pdp7DXU7Apk7EW4Xe_Oepe4GwbG5etr7A4PCm3e8PtRdPjw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEG8CBYxEuaCwib1OnANCqGXVUlpxoNLegu21tYu2cdpuhfrX-HXM5LFtKfTWWySPItszY3_2jL8BeGMLlWSJ57Ex6G7DTOLXJOWx1j7xhU2k8_R2eG8_2z4YfhnL8Qr87t_CUFplvyY2C_UkWLojH6TEvCWJzGTgu7SIb1ujj_VRTBWkKNLal9NoTWTXnf3C49vJh50t1PUG56PP3ze3467CQGwFdjK2SlhjfWIKP_FZrk2ecisLr5xBJKLkREtlMoegynL0RqVsaonDTQpntTNe4H9vwe1cyJR8LB_n54S_iWr5OukqsOBJl3SfCDUwP4k7Mc3eCyKjvLgdXsG4V1M1_4rXNtvg6B7c7fAr-9Qa3H1YcdUDWNvrIvQPYbqp62lAg2aIhlndEUSFigXPiAyAHVKKPBEpsVnF6r5QCDs8c_OgzbzhIWdTTVSyoQ4zemPJKLrAFg0N-1y3b6WqR3BwI3P9GFarULmnwNCIhPTO4lExHbrca-kQpkrl_FALq2QE7_pJLW1HdU4VN-ZlE3IXqkQVlKSCElUQwcZSum4pPv4jt97rp-wc_aQ8N8sIXi-b0UVpZnTlwinJIOrjVEznOhnizSkQnkbwpFX5sjMcF1UpeRZBfskYlgJEEX65pZpNG6pwRNd4Bs4jeNubzYWu_2OMz64f4ytYQ6crv-7s7z6HO5wQTpORtw6ri-NT9wLx2cK8bByBwY-b9rw_YcFSXw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Caphosol+for+prevention+of+oral+mucositis+in+pediatric+myeloablative+haematopoietic+cell+transplantation&rft.jtitle=British+journal+of+cancer&rft.au=Treister%2C+Nathaniel&rft.au=Nieder%2C+Michael&rft.au=Baggott%2C+Christina&rft.au=Olson%2C+Ellen&rft.date=2017-01-03&rft.issn=0007-0920&rft.eissn=1532-1827&rft.volume=116&rft.issue=1&rft.spage=21&rft.epage=27&rft_id=info:doi/10.1038%2Fbjc.2016.380&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_bjc_2016_380
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon